Target Search | CytoTargetDB

Only direct cytotoxic targets are shown

Gene

Drug Category

Drug Class

Binding Type

antigen recognition (3404)

other (145)

receptor ligand recognition (192)

Annotation Status

ai (3167)

manual_review_required (574)

Disease Type

CANCER (2959)

NON-CANCER (780)

Tissue

OncoTree Main Type

OncoTree Name

Items per page

Download CSV

Gene	NCT ID	Antigen/Ligand	Binding Type	Drug Name	Drug Category	Drug Class	Drug Description	Drug Mechanism of Action	Target Cytotoxicity Mechanism	Disease	Disease Type	Tissue	Annotation Status
CD8A	NCT05508009	CD8 alpha	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.	Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.	ATG antibodies bind CD8α on T cells and induce complement-dependent lysis and Fc-mediated effector killing (ADCC and phagocytosis), depleting CD8+ cells.	CKD Stage 4	NON-CANCER	Kidney	ai
IL2RA	NCT05508009	Interleukin-2 receptor alpha (CD25)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.	Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.	ATG antibodies bind CD25 on T cells, triggering complement-dependent lysis and Fc-mediated effector functions (ADCC and phagocytosis) that deplete the target cells.	CKD Stage 4	NON-CANCER	Kidney	ai
CD28	NCT05508009	CD28	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.	Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.	ATG binds CD28 on T cells (among other T‑cell antigens), leading to complement-dependent lysis and Fc-mediated ADCC/phagocytosis that depletes CD28+ T cells.	CKD Stage 4	NON-CANCER	Kidney	ai
PTPRC	NCT05508009	CD45 (protein tyrosine phosphatase receptor type C)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.	Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.	Polyclonal antibodies in ATG bind CD45 on T cells, activating complement and Fc-mediated effector functions (ADCC and phagocytosis) to deplete the bound cells.	CKD Stage 4	NON-CANCER	Kidney	ai
ITGAL	NCT05508009	LFA-1 alpha chain (CD11a)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.	Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.	ATG contains antibodies that bind CD11a (LFA-1) on T cells and deplete them via complement-dependent lysis and Fc-mediated effector functions (ADCC by NK cells and phagocytosis).	CKD Stage 4	NON-CANCER	Kidney	ai